Kansas Breast And Cervical Cancer Screening Program For Low-Income, Uninsured Women Runs Out Of Funding
The Kansas Early Detection Works program, which provides uninsured low-income women in the state with breast and cervical cancer screenings at no cost, has depleted its operating funds and will delay almost all cancer screenings until July 1, the Wichita Eagle reports.
Gen-Probe Launches In Europe CE-Marked APTIMA R HPV Assay For Detection Of Human Papillomavirus
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer.
Safety Concerns Over Merck's HPV Vaccine Gardasil Unfounded, CDC Officials Say
Safety concerns over Merck's human papillomavirus vaccine Gardasil are unfounded, and reports of serious adverse events are unrelated to the vaccine, CDC officials recently said, the Dallas Morning News reports.
Cervarix trade;, GSK's Cervical Cancer Vaccine, Wins Tender For UK National Immunisation Programme
GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was confirmed as the UK Department of Health's vaccine of choice for its national human papillomavirus (HPV) immunisation programme. The programme, which aims to protect against the two types of HPV that are responsible for approximately 70% of cervical cancers1, will start in September 2008 and will vaccinate girls aged 12 to 13 each year.
Are U.S. Mothers Ready To Vaccinate Their Daughters Against HPV?
Certain strains of human papillomavirus (HPV) are sexually transmitted and can cause cervical cancer and genital warts. In 2006, the U.S. Food and Drug Administration approved Gardasil, a prophylactic HPV vaccine marketed by Merck. It is recommended for girls and women 9 to 26 years old, but in almost all states, it is not mandated.
New Zealand Prime Minister Announces Funding For New HPV Vaccine Program
New Zealand Prime Minister Helen Clark on Friday announced a new program that will provide about $128 million over five years to vaccinate girls ages 12 to 18 against cervical cancer, the New Zealand Herald reports. As of Sept.
Mothers More Willing To Have Older Daughters Vaccinated Against HPV, Study Finds
Although CDC recommends that girls receive the human papillomavirus vaccine at age 11 or 12 to protect against cervical cancer before the onset of sexual activity, mothers of girls under age 13 are less willing to have their daughters vaccinated than mothers of older girls, a new study has found, the.
31 Million Dollars Allocated To National Breast And Ovarian Cancer Centre To Improve Access To Breast Prostheses, Australia
National Breast and Ovarian Cancer Centre has welcomed an additional $31 million funding over five years from the Australian Government to allow all Australian women who have had a mastectomy as a result of breast cancer to access external prostheses.
HPV Testing Offers Women Protection For Twice As Long As Smear Testing
The long term findings of a study carried out at Hammersmith hospital reveal that testing for Human Papilloma Virus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing. Results of the research - led by Professor Jack Cuzick of Barts and The London School of Medicine and Dentistry - are published in the International Journal of Cancer.
Cervarix TM Provides Longest Duration Of Sustained Neutralising Antibodies Reported For Any Vaccine Against HPV 16 And 18 Date
New data from an extended follow-up study show that CervarixTM generates sustained high levels of neutralising antibodies against the two most common cervical cancer-causing virus types for up to 6.4 years.4 This is the longest duration of sustained neutralising antibody levels reported against both virus types HPV 16 and 18 with a cervical cancer vaccine to date.